Previous 10 | Next 10 |
AC Immune (ACIU) announced that its anti-pTau vaccine candidate, a collaboration with Janssen Pharmaceuticals of Johnson & Johnson (JNJ), has generated positive interim results from an ongoing Phase 1b/2a clinical trial involving elderly patients with early Alzheimer’s di...
AC Immune SA (ACIU) +112% as its vaccine generates potent anti-pTau antibody response in a phase 1b/2a study.RCM Technologies, Inc. (RCMT) +92%.Sundial Growers Inc. (SNDL) +48%.MicroVision, Inc. (MVIS) +44% after long range lidar update.Monopar Therapeutics (MNPR) +41% on poten...
Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease ACI-35.030 was safe and well tolerated with no safety concerns observed. Results supp...
LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that the first patient has been scanned in a first-in-human study of its...
ATA Creativity Global (AACG) +163%.Anavex Life Sciences (AVXL) +83%.Profire Energy (PFIE) +57%.Theratechnologies (THTX) +56% on FDA fast track designation for the treatment of Sortilin-expressing Cancers.Cyclerion Therapeutics (CYCN) +34%.Atossa Therapeutics (ATOS) +33%.Enservco Corporat...
Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors High-affinity antibodies against extracellular components of the inflammasome pathway show inhibition of target inflammatory responses LAUSANNE, Switzerland, Jan. ...
Mizuho Securities upgrades Eli Lilly ([[LLY]] +4.4%) to buy from neutral rating citing ‘significantly more upside as donanemab adds another important leg to the story.’ The price target is also raised to $222 from $164 per share implying ~16.3% to the previous close.Lilly shares...
Goldman Sachs analyst Terence Flynn said he expected Eli Lilly ([[LLY]] +11.7%) shares to react favorably to positive Phase 2 data of donanemab in Alzheimer's, given that his own expectations for success were low. He also views the news as an "incremental positive" for Biogen ([[BIIB]] +7.3%)...
Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital Proprietary SupraAntigen TM platform continues to accelerate development of first- and best-in class antibody therapeu...
Prof. June is a world authority on immune tolerance and adoptive immunotherapy Appointment re affirm s AC Immune’s scien tific leadership in neurodegeneration LAUSANNE, Switzerland, Nov. 20, 2020 (GLOBE NEWSWIRE) -- AC Immune ...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...